Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine

被引:16
作者
Hali, F. [1 ]
Kerouach, A. [1 ]
Alatawna, H. [2 ]
Chiheb, S. [1 ]
Lakhdar, H. [1 ]
机构
[1] Ibn Rochd Univ Hosp, Dept Dermatol & Venereol, Casablanca, Morocco
[2] Ctr Pathol, Ibn Zohr, Casablanca, Morocco
关键词
D O I
10.1111/ced.15007
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A case of linear IgA bullous dermatosis developing 3 days after the second dose of Oxford AstraZeneca COVID-19 vaccine in an adult patient, suggesting a possible causal association. It is worth keeping in mind that COVID-19 vaccination could induce immune-mediated bullous disease in susceptible people.
引用
收藏
页码:611 / 613
页数:3
相关论文
共 5 条
[1]  
Alberta-Wszolek Lauren, 2009, Dermatol Online J, V15, P3
[2]   Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms [J].
Chanal, J. ;
Ingen-Housz-Oro, S. ;
Ortonne, N. ;
Duong, T. -A. ;
Thomas, M. ;
Valeyrie-Allanore, L. ;
Lebrun-Vignes, B. ;
Andre, C. ;
Roujeau, J. -C. ;
Chosidow, O. ;
Wolkenstein, P. .
BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (05) :1041-1048
[3]   Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature [J].
Coto-Segura, P. ;
Fernandez-Prada, M. ;
Mir-Bonafe, M. ;
Garcia-Garcia, B. ;
Gonzalez-Iglesias, I. ;
Alonso-Penanes, P. ;
Gonzalez-Guerrero, M. ;
Gutierrez-Palacios, A. ;
Miranda-Martinez, E. ;
Martinon-Torres, F. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (01) :141-143
[4]   Drug-induced Linear IgA Bullous Dermatosis: A Case Report and Review of the Literature [J].
Lammer, Judith ;
Hein, Ruediger ;
Roenneberg, Sophie ;
Biedermann, Tilo ;
Volz, Thomas .
ACTA DERMATO-VENEREOLOGICA, 2019, 99 (06) :508-515
[5]   Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination [J].
Tomayko, Mary M. ;
Damsky, William ;
Fathy, Ramie ;
McMahon, Devon E. ;
Turner, Noel ;
Valentin, Monica N. ;
Rallis, Tena ;
Aivaz, Ohara ;
Fox, Lindy P. ;
Freeman, Esther E. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 148 (03) :750-751